Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 135 publications
Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.
Journal: The Journal of clinical investigation
Published: June 09, 2026
Targeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancer.
Journal: Clinical proteomics
Published: February 12, 2026
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 27, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.
Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: April 26, 2025
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer.
Journal: Science advances
Published: April 23, 2025
RNAs anchoring replication complex control initiation and firing of DNA replication.
Journal: Research square
Published: February 20, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.
Journal: The Journal of clinical investigation
Published: February 12, 2025
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Journal: Nature communications
Published: February 05, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
Journal: iScience
Published: January 27, 2025
Last Updated: 09/26/2026